Accordingly, RAAS-targeted therapy in SA-AKI should be interpreted within a context-dependent framework: exogenous Ang II may benefit selected patients with impaired effective Ang II generation, whereas ACE2/Ang-(1-7)/Mas-based or anti-angiotensin II type 1 receptor (AT1R) strategies may be more relevant in settings of maladaptive Ang II signaling. This evidence concerns the gene ACE2 and acute kidney injury.